Log in

Children ages 5-11 now eligible for COVID-19 vaccination

Posted

WARRENSBURG — The Pfizer-BioNTech COVID-19 vaccine has been approved for emergency use by both the Food and Drug Administration and the Centers for Disease Control for children ages 5 to 11. 

The Pfizer-BioNTech vaccine was previously authorized for use in individuals 12 and older. 

The Missouri Department of Health and Senior Services have adopted the CDC’s recommendations. 

Based on the state’s amended standing order, Johnson County Community Health Services will administer the vaccine to children ages 5 to 11.

Beginning Wednesday, Nov. 10, JCCHS will offer the Pfizer-BioNTech COVID-19 Vaccine to anyone age 5 and older during the agency’s Walk-in Wednesday COVID Vaccine Clinic. The walk-in clinics are from 1 to 4:30 p.m. every Wednesday but could change with the upcoming holidays.  

Vaccines will be offered while supplies last.  No appointment is necessary.

The vaccine for children ages 5-11 is a smaller dose, which is a third of the dosage for individuals 12 years and older. 

The Pfizer-BioNTech COVID-19 vaccine is a series of two doses, administered three weeks apart, for all eligible individuals.

In clinical trials, the Pfizer-BioNTech vaccine was found to be more than 90 percent effective in preventing COVID-19 in children ages 5-11. 

Vaccine side effects were mild and similar to those seen in adults and with other vaccines recommended for children. 

These are normal signs that their body is building protection, but they should go away in a few days. The most common side effect was a sore arm. 

Whether a child or teen gets vaccinated is decided by their family. 

Vaccine concerns and side effects should be discussed with a family physician. 

JCCHS continues to follow guidance from the CDC and the Missouri Department of Health and Senior Services. 

For more information about the COVID-19 vaccine, visit MOStopsCovid.com. 

For answers to frequently asked questions, visit covidvaccine.mo.gov/facts/#parent-kids.



Comments

No comments on this item Please log in to comment by clicking here


X